Search Medical Condition
Please enter condition
Please choose location

Thrombosis Clinical Trials

A listing of Thrombosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (233) clinical trials

To compare the efficacy of once daily injections in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy Patient Inclusion Criteria: Cancer patients with metastatic or locally advance solid tumor of the lung, pancreas, stomach, colon/rectum, bladder or ovary, planned ...

Phase

EINSTEIN CHOICE is a phase II study designed to evaluate whether once-daily rivaroxaban in doses of 10mg or 20mg is superior to aspirin for the prevention of symptomatic recurrent DVT and/or PE in patients who have completed between six and 12 months of anticoagulant therapy. The study will include approximately ...

Phase

Evaluation of Soluble Fibrin in Thrombosis Exclusion

Rationale. Pulmonary embolism (PE) is a major public health problem. D-dimer (D-Di) assay is useful to exclude VTE (DVT and PE) but not specific, requiring irradiating and expensive imaging tests. Preliminary results suggest that the Soluble Fibrin (SF) assay has a sensitivity comparable to the D-Di one, but a higher ...

Phase N/A

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates

Neonates and infants aged less than 6 months who pass the screen of in- and exclusion criteria, who have been treated for at least five days with heparin and /or VKA for confirmed symptomatic or asymptomatic arterial or venous thrombosis are eligible for the study. Study treatment consists of a ...

Phase

Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon

Bakground and study rationale: Left atrial (LA) thrombi are found in 2.5 - 18% of subjects with atrial fibrillation (AF) depending on the subject population. Subjects with LA thrombi have a particularly increased risk for cerebral and peripheral embolism. Consequently, oral anticoagulation is recommended in those subjects. Transesophageal echocardiography (TEE) ...

Phase

Safety and Tolerability Study of BMS-986177 in Healthy Subjects

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy subjects

Phase

Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting

The new P2Y12 inhibitors prasugrel (Efient-Effient) and ticagrelor (Brilique-Brilinta) have shown promising results in the respective TRITON and PLATO trials making of prasugrel and ticagrelor recommended first line treatments for acute coronary syndrome ACS (ESC Guidelines: Class 1 LOE B). These two drugs showed superiority over clopidogrel in ACS patients ...

Phase

Utilization of TEG to Monitor Rivaroxaban Activity

Rivaroxaban is a novel factor Xa inhibitor that is widely used for stroke prevention in nonvalvular atrial fibrillation, treatment of venous thromboembolism (VTE), and for VTE prophylaxis in patients undergoing knee or hip replacement surgery. Current standard measurements of coagulation are relatively poor at reliably measuring detecting Rivaroxaban effects and ...

Phase N/A

Angel Catheter Post Market Registry

The Registry population will include all consecutive patients in whom the Angel Catheter is placed at participating sites. Information about the use of the catheter will be collected from placement through three days after device removal, or through death or discharge, whichever occurs first. Date of discharge/transfer from the Critical ...

Phase N/A

Apixaban Discontinuation Prior to Major Surgery

This study will estimate for what proportion of patients a 48 hour pre-procedure apixaban discontinuation is sufficient to achieve minimal apixaban plasma levels (less than 30 ng/mL) prior to surgery. The investigators hypothesize that this portion will be 80-95%. All patients will have a blood draw at 48 hours prior ...

Phase N/A